Independent medical education
The medical education activities below are non-promotional, evidenced-based, fair-balanced and can be accredited or non-accredited. The activities are developed independently by third-party providers through an educational grant from Janssen to enhance the knowledge, skills, and performance of healthcare professionals, patients, and communities.
Bladder cancer
- AMCP: Addressing Barriers in Advancing Equitable Biomarker Testing in Community Oncology
- Beyond The Guidelines: Urologic Oncology Investigators Provide Perspectives on the Optimal Management of Urothelial Bladder Cancer
- Breakfast with the Investigators: Urothelial Bladder Cancer
- Candid Conversations on Modern Urothelial Cancer Management: Personalizing Patient Care Using the Latest Evidence and Innovative Therapeutic Strategies
- Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum
- Keeping It Current: Latest European Updates in Prostate and Bladder Cancer
- Oncology Today with Dr Neil Love: Special Edition — Management of Urothelial Bladder Cancer
Prostate cancer
- AMCP: Addressing Barriers in Advancing Equitable Biomarker Testing in Community Oncology
- Annual Meeting Genitourinary Cancer Tracks Bundle
- An Asembia Satellite Symposium: Innovations in Prostate Cancer: Unveiling Novel Therapies and the Role of the Specialty Pharmacist
- AUA2024 Prostate Cancer Courses and On-Demand Activities
- Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Prostate Cancer
- Expert Second Opinion: Investigators Discuss How They and Their Colleagues Apply Available Clinical Research in the Care of Patients with Prostate Cancer An Independent Satellite Symposium (ISS) Held in Conjunction with the 2024 American Urological Association (AUA) Annual Meeting
- Elevating Optimal Care for Prostate Cancer: Applying Personalized Treatment Options to Improve Outcomes
- Evolving Paradigm of PARP Inhibitors and Combination Therapies for mCRPC
- Expert Context from AUA 2024: Revolutionizing Prostate Cancer Treatment
- “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients with CRPC
- Improving the Overall Safety and Quality of Care for Your Patients with Metastatic Hormone-Sensitive Prostate Cancer: How Does Your Approach Compare with the Experts?
- Inside the Issue: Exploring the Current and Future Management of High-Risk, Hormone-Sensitive Nonmetastatic Prostate Cancer
- Metastatic Prostate Cancer: Current Treatment Advances: Part I of Living with Metastatic Prostate Cancer
- Medscape Onsite: Prostate and Bladder Cancer Updates
- Prostate Cancer Master Class: Addressing Challenges in A New Era of Personalized Care
- Second Opinion: Investigators Discuss How They and Their Colleagues Apply Available Clinical Research in the Care of Patients with Prostate Cancer
- The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion
- (2024 PUPC) Evidence-Based Strategies to Optimize Prostate Cancer Screening and Outcomes
Non-small cell lung cancer
- AMCP: Addressing Barriers in Advancing Equitable Biomarker Testing in Community Oncology
- AdaptiveCME: Advances in Molecular Targeted Therapies for NSCLC
- Biomarkers in NSCLC: From Detection to Novel Therapeutics and Decision-Making
- Biomarker Testing: Shaping Personalized Medicine (Episode 2)
- Can Molecular Testing Identify Which mNSCLC Patients Will Benefit From New Targeted Tx?
- Clinical Trials: How They Transform the Treatment of Cancer
- Highlights from Madrid on Perioperative Immunotherapy in Early-Stage NSCLC
- Highlights from Madrid on Targeted Therapy for Advanced NSCLC
- Interprofessional Approaches to Managing Adverse Events in EGFR-Mutated NSCLC
- Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced and Early- Stage NSCLC
- Navigating Rapid Sea Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC
- New Horizons in the Treatment and Management of Non-Small Cell Lung Cancer (NSCLC): Managed Care Considerations on the Role of EGFR Exon 20-Targeted Therapies
- Non–Small Cell Lung Cancer: Treatment Updates From the Floor of ESMO 2023
- Novel Therapeutic Approaches for EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer: An Oncology Pharmacy Perspective
- Novel Therapeutics: Changing the Treatment Landscape for NSCLC (Episode 3)
- Practical Strategies for Preventing and Mitigating Toxicities of Targeted Therapy (Episode 4)
- Recorded Presentations From The NCCN 2023 Congress: Biomarkers in Solid Tumors
- Second Opinion: Investigators Discuss How They Apply Available Clinical Research in the Care of Patients with Non-Small Lung Cancer with EGFR Mutations
- The Evolution of Biomarker Testing: Revolutionizing Treatment of NSCLC (Episode 1)
- The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
- Video Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Non-Small Cell Lung Cancer
- 2024 Great Debates & Updates in Lung Cancers Targeted Strategies in the Management of Non-Small Cell Lung Cancer: A Focus on EFGR Gene Mutations
Lymphoma
- Highlights From Bruton’s Tyrosine Kinase Inhibitors: Updates and Advancements in the Treatment and Management of CLL/SLL
- New Pathways in the Treatment of Mantle Cell Lymphoma
- What I Tell My Patients: New Treatments and Clinical Trials —Chronic Lymphocytic Leukemia
Multiple myeloma
- 7th Annual Live Medical Crossfire®: Hematologic Malignancies
- (2023 Specialty Pharmacy NEXT) Novel Targeted Therapies for Relapsed/Refractory Multiple Myeloma
- CCO at ASCO 2023 Symposium: Exploring the Progress and Evolving Therapeutic Paradigm in Multiple Myeloma
- Current and Emerging Treatment Strategies in Multiple Myeloma: Managed Care Considerations for Improved Patient Outcomes
- Delivering Change: Mechanisms to Address Racial Healthcare Disparities in Multiple Myeloma
- Demystifying the Details of T-Cell-Engaging Bispecific Antibodies: Establishing a Foundation for Oncology Pharmacists
- Individualized Strategies for Relapsed/Refractory Multiple Myeloma: Navigating Complexity with BCMA-Targeted and Novel Bispecific Antibodies
- Keeping Up with CAR T-cell Therapy: A Case-based Challenge of CART in NHL + MM
- Management of CRS and ICANS with CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma
- Multiple Myeloma: 2023 ASH Annual Meeting Highlights from San Diego
- Overcoming Barriers to Care in Multiple Myeloma: Recognizing the Problem and Focusing on Solutions
- Oncology Morning Commute: Emerging Data on BTCE in RRMM
- Oncology Morning Commute: Tying a T-cell to the Tumor Cell in RRMM
- Oncology Morning Commute: Using Bispecifics for the Treatment of Multiple Myeloma in Clinical Practice
- Recent Advances in BCMA-Directed Treatment in Multiple Myeloma – Insights and Application for Managed Care
- Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations
- The Heterogeneity, Therapeutic Advancements, and Updated Guidelines for the Treatment of RRMM
- The New ABCs of Myeloma Care: Enhancing Outcomes With CD38 Antibodies, BCMA Immunotherapy, and Unique Bispecific Platforms
- Updates From the 2023 Summer Meetings: Bispecific Antibodies in Multiple Myeloma